Decisions With Patients and Families Regarding Aducanumab in Alzheimer Disease, With Recommendations for Consent
- 25 January 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 98 (4) , 154-159
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- What the Aducanumab Approval Reveals About Alzheimer Disease ResearchJAMA Neurology, 2021
- Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive ImpairmentJAMA, 2021
- Revisiting FDA Approval of AducanumabNew England Journal of Medicine, 2021
- Ethical Considerations in Dementia Diagnosis and CareNeurology, 2021
- Three FDA advisory panel members resign over approval of Alzheimer’s drugBMJ, 2021
- Bayes analysis supports null hypothesis of anti‐amyloid beta therapy in Alzheimer's diseaseAlzheimer's & Dementia, 2021
- The FDA and the Importance of TrustNew England Journal of Medicine, 2020
- FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019JAMA Internal Medicine, 2020
- National Health Expenditure Projections, 2019–28: Expected Rebound In Prices Drives Rising Spending GrowthHealth Affairs, 2020
- Approving a Problematic Muscular Dystrophy DrugJAMA, 2016